Aruna Kamineni, PhD, MPH, came to Kaiser Permanente Washington Health Research Institute in 2009 with a wealth of experience in chronic disease epidemiology. Dr. Kamineni has expertise in using case-control methods to evaluate screening efficacy, and her research focuses on addressing evidence gaps for clinical guidelines, particularly for cervical and colorectal cancer prevention. A substantial portion of her work has focused on developing infrastructure and methods for research using electronic clinical and administrative health care data.
Since 2011, Dr. Kamineni has participated in the National Cancer Institute’s Population-based Research to Optimize the Screening Process (PROSPR) consortium to evaluate and improve cancer screening in U.S. community settings. As a principal investigator for multisite cervical and colorectal cancer PROSPR Research Centers, Dr. Kamineni is leading and collaborating on work to determine how to optimally use screening tests and consider how to tailor screening for population subgroups.
Dr. Kamineni’s research goals include studying the impact of human papillomavirus (HPV) DNA testing and HPV vaccination on cervical cancer and screening programs. Multidisciplinary collaboration is a valued and important driver of Dr. Kamineni’s research and she embraces a team science approach to optimizing cancer prevention.
Cervical cancer; colorectal cancer; screening; disparities
Electronic clinical and administrative data infrastructure development for research; case-control studies; team science
Chubak J, McLerran D, Zheng Y, Singal AG, Corley DA, Doria-Rose VP, Doubeni CA, Kamineni A, Haas JS, Halm EA, Skinner CS, Zauber AG, Wernli KJ, Beaber EF. Receipt of colonoscopy following diagnosis of advanced adenomas: an analysis within integrated healthcare delivery systems. lid - 10.1158/1055-9965.epi-18-0452 [doi] Cancer Epidemiol Biomarkers Prev. 2018 Nov 20. pii: 1055-9965.EPI-18-0452. doi: 10.1158/1055-9965.EPI-18-0452 [Epub ahead of print] PubMed
Kamineni A, Tiro JA, Beaber EF, Silverberg MJ, Wheeler CM, Chao CR, Chubak J, Skinner CS, Corley DA, Kim JJ, Balasubramanian BA, Doria-Rose VP. Cervical cancer screening research in the PROSPR I Consortium: rationale, methods, and baseline findings from a U.S. cohort. Int J Cancer. 2018 Oct 24. doi: 10.1002/ijc.31940. [Epub ahead of print]. PubMed
Selby K, Jensen CD, Lee JK, Doubeni CA, Schottinger JE, Zhao WK, Chubak J, Halm E, Ghai NR, Contreras R, Skinner C, Kamineni A, Levin TR, Corley DA. Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection: A Community-Based Cohort Study. Ann Intern Med. 2018;169(7):439-447. doi: 10.7326/M18-0244. Epub 2018 Sep 18. PubMed
Mazor KM, Kamineni A, Roblin DW, Anau J, Robinson BE, Dunlap B, Firneno C, Gallagher TH. Encouraging patients to speak up about problems in cancer care. J Patient Saf. 2018 Jun 27. doi: 10.1097/PTS.0000000000000510. [Epub ahead of print]. PubMed
Singal AG, Corley DA, Kamineni A, Garcia M, Zheng Y, Doria-Rose PV, Quinn VP, Jensen CD, Chubak J, Tiro J, Doubeni CA, Ghai NR, Skinner CS, Wernli K, Halm EA. Patterns and predictors of repeat fecal immunochemical and occult blood test screening in four large health care systems in the United States. 2018 May;113(5):746-754. doi: 10.1038/s41395-018-0023-x. Epub 2018 Feb 27. PubMed
Balasubramanian BA, Garcia MP, Corley DA, Doubeni CA, Haas JS, Kamineni A, Quinn VP, Wernli K, Zheng Y, Skinner CS. Racial/ethnic differences in obesity and comorbidities between safety-net- and non safety-net integrated health systems. Medicine (Baltimore). 2017;96(11):e6326. doi: 10.1097/MD.0000000000006326. PubMed
Habbema D, Weinmann S, Arbyn M, Kamineni A, Williams AE, M C M de Kok I, van Kemenade F, Field TS, van Rosmalen J, Brown ML. Harms of cervical cancer screening in the United States and the Netherlands. Int J Cancer. 2017 Mar 1;140(5):1215-1222. doi: 10.1002/ijc.30524. PubMed
Shortreed SM, Johnson EJ, Rutter CM, Kamineni A, Wernli KJ, Chubak J. Cohort restriction based on prior enrollment: Examining potential biases in estimating cancer and mortality risk. Obs Stud. 2016 Aug;2:51-64. Epub 2016 Sep 26. PubMed
Zhang M, Wang Z, Obazee O, Jia J, Childs EJ, Hoskins J, Figlioli G, Mocci E, Collins I, Chung CC, Hautman C, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Kamineni A, Kolonel LN, Kulke MH, Malats N, Olson SH, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Brais L, Bueno-de-Mesquita HB, Basso D, Berndt SI, Boutron-Ruault MC, Bijlsma MF, Brenner H, Burdette L, Campa D, Caporaso NE, Capurso G, Cavestro GM, Cotterchio M, Costello E, Elena J, Boggi U, Gaziano JM, Gazouli M, Giovannucci EL, Goggins M, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Hu N, Hunter DJ, Iskierka-Jazdzewska E, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Neale RE, Oberg AL, Panico S, Patel AV, Peeters PH, Peters U, Pezzilli R, Porta M, Purdue M, Quiros JR, Riboli E, Rothman N, Scarpa A, Scelo G, Shu XO, Silverman DT, Soucek P, Strobel O, Sund M, Malecka-Panas E, Taylor PR, Tavano F, Travis RC, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vashist Y, Vodicka P, Wactawski-Wende J, Wentzensen N, Yu H, Yu K, Zeleniuch-Jacquotte A, Kooperberg C, Risch HA, Jacobs EJ, Li D, Fuchs C, Hoover R, Hartge P, Chanock SJ, Petersen GM, Stolzenberg-Solomon RS, Wolpin BM, Kraft P, Klein AP, Canzian F, Amundadottir LT. Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget. 2016 Oct 11;7(41):66328-66343. doi: 10.18632/oncotarget.11041. PubMed
Hubbard R, Johnson E, Chubak J, Wernli KJ, Kamineni A, Bogart A, Rutter C. Estimating screening test effectiveness when screening indication is unknown using generalized linear finite mixture models. Health Services Outcomes Res Methodol.2017 17(2):101-112.
Research informs care as Kaiser Permanente Washington, exceeding 80 percent screening rate, launches home-based 'FIT First' pilot.
Drs. Kamineni and Chubak are among leaders of 2 new large PROSPR awards from NCI for cervical and colorectal cancer screening research.
Read it in News and Events.
A Kaiser Permanente-led BCSC study is among the largest ever to evaluate adding MRI surveillance for breast cancer survivors.